Dr. Tony S. Fu, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 636 Church St Ste 222, Evanston, IL 60201 Phone: 847-328-3913 Fax: 847-328-3952 |
Dr. Jill Christina Anderson, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1704 Maple Ave, Suite 200, Evanston, IL 60201 Phone: 847-926-0106 Fax: 312-694-0202 |
Dr. Leonard Levitt, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1101 Howard St, Ste 204, Evanston, IL 60202 Phone: 847-733-9445 Fax: 847-733-9447 |
Lawrence E Levine, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 800 Austin East Tower #460, Evanston, IL 60202 Phone: 847-864-0370 Fax: 847-864-0385 |
Madhuri V Konanahalli, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1000 Central St Ste 800, Evanston, IL 60201 Phone: 847-663-8060 Fax: 847-663-1027 |
Lynne R. Eramo, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 414 Church St, Evanston, IL 60201 Phone: 847-491-0539 Fax: 847-491-0762 |
Ashley Nicole Millard-garcia, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1630 Sherman Ave, Evanston, IL 60201 Phone: 847-535-6464 Fax: 224-271-4870 |
News Archive
Neutrophils, a type of white blood cell, are the immune system's all-terrain vehicles. The cells are recruited to fight infections or injury in any tissue or organ in the body despite differences in the cellular and biochemical composition.
A team of researchers based in Turkey has now studied the pandemic's effect on emergency medical services (EMS). Their study, titled "Effects of COVID‐19 pandemic on emergency medical services," was published in the latest issue of The International Journal of Clinical Practice.
The Royal Victoria Hospital (RVH) in Barrie, Ontario is the first Canadian hospital to order a RIVA System (Robotic IV Automation System) - a self-contained unit for filling IV syringes and bags from Intelligent Hospital Systems (IH Systems).
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.
› Verified 4 days ago